Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>While maintaining rigid cost controls generally (OpEx declined 26% y/y in FY 25), AEMD continues pre-clinical research and analysis of the Hemopurifier in areas outside of oncology.</li><li>Results from a preclinical ex vivo study were published in bioRxiv in May 2025 and demonstrate that the Hemopurifier removed 98.5% of platelet-derived extracellular vesicles (PD-EVs) from human plasma.</li><li>This supports moving forward with the ongoing oncology study in Australia, launching a similar study in India and also point to other potential applications of the Hemopurifier in EV-associated diseases.</li></ul>

While maintaining rigid cost controls generally (OpEx declined 26% y/y in FY 25), AEMD continues pre-clinical research and analysis of the Hemopurifier in areas outside of oncology.Results from a preclinical ex vivo study were published in bioRxiv in May 2025 and demonstrate that the Hemopurifier removed 98.5% of platelet-derived extracellular vesicles (PD-EVs) from human plasma.This supports moving forward with the ongoing oncology study in Australia, launching a similar study in India and also point to other potential applications of the Hemopurifier in EV-associated diseases.

Aethlon Medical  - While maintaining rigid cost controls generally (OpEx declined 26% y/y in FY 25)